Jacqueline Anders
Family · North Webster, INNPI 1881075877
Payments from drug & device makers
Across 158 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$757
- GSK$570
- Lilly USA, LLC$419
- Axsome Therapeutics, Inc.$369
- Novo Nordisk$264
- Otsuka America Pharmaceutical, Inc.$197
- plus $719 from 17 others
What the payments were for
- Food & beverage$3,296100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $757 |
| GSK | 24 | $570 |
| Lilly USA, LLC | 23 | $419 |
| Axsome Therapeutics, Inc. | 16 | $369 |
| Novo Nordisk | 13 | $264 |
| Otsuka America Pharmaceutical, Inc. | 6 | $197 |
| Amgen | 7 | $116 |
| Organon | 1 | $81 |
| Gilead | 1 | $65 |
| Abbott | 3 | $60 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| AstraZeneca | 4 | $51 |
| Astellas Pharma US Inc | 2 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Exact Sciences | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Boehringer Ingelheim | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,296 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 55 | $83,278 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $59,211 |
| MounjaroTirzepatide | 50 | $56,709 |
| JanuviaSitagliptin Phosphate | 39 | $55,349 |
| OzempicSemaglutide | 39 | $47,300 |
| EliquisApixaban | 37 | $35,607 |
| FarxigaDapagliflozin Propanediol | 11 | $18,533 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $17,459 |
| TradjentaLinagliptin | 16 | $17,434 |
| VraylarCariprazine Hcl | 11 | $15,163 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $14,735 |
| MyrbetriqMirabegron | 13 | $14,583 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $12,908 |
| JardianceEmpagliflozin | 11 | $9,162 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $7,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $419 | $139,987105 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $570 | $73,94691 claims |
| MerckJanuvia | $17 | $55,34939 claims |
| Novo NordiskOzempic | $264 | $47,30039 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $51 | $35,99329 claims |
| Boehringer IngelheimTradjenta, Jardiance, Stiolto Respimat | $30 | $33,67442 claims |
| AbbVieVraylar | $757 | $15,16311 claims |
| Astellas Pharma US IncMyrbetriq | $41 | $14,58313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.
Other family in North Webster
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.